Camlin Fine Sciences Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Core business grew ~15% YoY despite price headwinds: Volume growth in Blends and the vanillin ramp-up offset southbound product prices, while gross margin crossed 50% in H2 after a two-year slog.
• The vanillin waiting game: Management is deliberately holding back volume commitments, betting that customer destocking and the EU's 131% preliminary anti-dumping duty will force buyers to accept higher prices in a few quarters.
• Discontinued operations are finally ring-fenced: The Board abandoned the loss-making Diphenol and China vanillin units, triggering a one-time INR14 crore cleanup charge but promising a 90% cut in Europe employee costs and a path to INR4-5 crores annual cash burn by FY27.
• Blends is the steady compounder: The business grew 17-18% YoY to INR878 crores, management is guiding ~20% organic growth, and the pending Vinpai acquisition could lift that to 25%.
• What to watch next quarter: Whether vanillin realizations actually tick up toward the $15 range, the Vinpai deal closing by July end, and any clarity on tariff impacts that management admits it cannot yet project.

The Vanillin Pivot: Pricing Power vs. Patience

• The core trade-off: Management is controlling vanillin sales volumes now, willing to forgo near-term revenue to capture higher realizations later, framing it as a choice between $12 today and $15 in a couple of quarters.
• Customer destocking is the near-term drag: Buyers stocked up on lower-priced material and will negotiate hard until their inventory positions become critical, a dynamic management expects to resolve over the next few months.
• EU anti-dumping duty as a catalyst: The preliminary 131% duty creates room for at least a 10-15% price increase in Europe from current levels, and the fact that large players are now approaching Camlin for volume commitments signals the duty is likely to be confirmed.
• Capacity ramp is deliberately gradual: Management could reach 100% utilization faster but warns that flooding the market in year one would be detrimental to prices, so the target is 100% over two years.
• Cost structure improves with scale: Cost of production sits at $9 at 45% utilization; breakeven is 70-75%, beyond which costs should fall below $9, adding a margin tailwind as volumes ramp.
• US market is the early mover: Sales in the US are already growing as some customer stock releases happen, and higher prices in the $15 range should start reflecting in realizations over the next few months.

Momaya: "One is you don't want to sign very large volume commitments. Second is, also some of these buyers have already bought lower-priced material and have stock. So they're also — they will also wait it out and negotiate hard till such time as their stock positions become critical. So, it's a waiting game."

Blends: The Growth Engine

• 17-18% YoY growth to INR878 crores: Driven by North America, India, and Mexico, with the CFS Vitafor acquisition contributing ~INR85 crores over nine months.
• Guidance raised to ~20% organic: Management expects to sustain this pace over the next 2-3 years, with growth coming from all existing geographies plus new markets in the Middle East, Africa, and Asia.
• Vinpai acquisition adds a 5-point kicker: If the deal closes by July end as expected, blends growth could reach 25%, though this is not baked into the base 20% guidance.
• Margin trajectory improving: EBITDA margins for blends are expected to sit in the high teens and move toward 20% as geographies mature, though management declined to break out segment-level margins citing competitive sensitivity.
• Q4 seasonality masked underlying momentum: Blends revenue was slightly muted by an extended holiday season in LatAm and Central America, effectively compressing the quarter to two months of business, plus delayed fishing seasons pushing sales into April/May.
• Italy blends business is small but growing: Currently INR50-60 crores annually, with some of the 20% growth expected to come from this geography as focus shifts to the ingredient business in Europe.

Discontinued Operations: The Cleanup

• What was abandoned: The Diphenol unit in Europe and the erstwhile vanillin manufacturing unit in China, both of which had already stopped production two years ago, were formally discontinued by the Board this quarter.
• One-time hit taken: INR22-23 crores reported in discontinued operations, of which ~INR14 crores were non-routine one-time expenses from plant cleanup after the abandonment decision.
• Structural cost reduction ahead: Annual Europe employee costs of INR16 crores will reduce by at least 90% next year, and the ongoing cash burn of INR8 crores per quarter should last only a couple more quarters.
• Path to INR4-5 crores annualized: By FY27, the residual cash burn from mothballed assets is expected to settle at INR4-5 crores per year, with assets being mothballed rather than dismantled.

Parab: "These both have had stopped 2 years back, and the Board has decided to discontinue or abandon this business, and hence, as per the Indian Accounting guidelines, we have segregated our results into 2; one, of a core business or what we call technically as a continuing operations and a discontinued operations."

Margins: The Gross Margin Swing

• Gross margin crossed 50% in H2 FY25: This is a milestone after roughly two years below that threshold, driven by incremental aroma revenue and the swing from losing money on Catechol to profitable vanillin conversion.
• The Catechol-to-vanillin swing is structural: When Catechol is sold standalone, it loses money; converting it to vanillin captures a margin swing that management expects to continue as vanillin volumes ramp.
• Offset by broad-based price pressure: Several other products face aggressive competition, particularly from China, keeping a lid on the overall gross margin range.
• Target range is 45-55%: Management hopes the mix shifts toward the upper end, closer to 55%, as vanillin becomes a larger share of revenue, but the range depends on product mix and market behavior.
• Employee expenses jumped 25% YoY: Driven by the Vitafor acquisition, annual salary cycles in the Americas and Europe, and hiring for anticipated growth, a cost layer that needs revenue growth to absorb.
• Depreciation also stepped up: A QoQ jump came from regrouping, the Vitafor addition, and lease assets where the company chose leases over purchases to conserve cash.

Momaya: "So it's — when you look at it, we lose money on Catechol. As soon as we convert it to vanillin, there is a swing in gross margin. So, that swing in gross margin will continue to happen on one side. On the other side, there are several products where we are seeing a lot of price pressure and a lot of competition, very aggressive competition."

External Risks: Tariffs, Competition, and the China Factor

• Tariff war is a known unknown: Management described the situation as changing daily and declined to project impacts, though it noted India should not be worse off than China and may have equal grounds or some advantage.
• Chinese competition is aggressive on pricing: Pricing pressure exists on all products except vanillin in two markets, with China-based competitors driving the aggression.
• Solvay's cost position is lower than assumed: Per an analyst's math, Solvay's cost of production was thought to be $17-20, but management corrected that it is much lower, in the $10 range, implying a more competitive landscape than some investors model.
• Vanillin price ceiling is uncertain: When asked if prices could move to $20, management responded "Who knows? Difficult to say," signaling no conviction on a sharp upside beyond the $15 range currently targeted.

Momaya: "So, it's very difficult to answer that question, Surya, because everything keeps moving every day. So, who knows what tariff will come on which product in which country. So, it's very, very difficult really to project what will happen."

Other Bets: Lockheed, Branded Products, and Capex

• Lockheed Martin is still a zero-revenue story: The first battery has been installed and the company is waiting for feedback, but there are no orders and no timeline, with management stating it is "not in our hands."
• Branded DHA and Omega products could inflect in FY26: Some contracts are being negotiated, and if they come to fruition in the next 3-4 months, they could drive a big jump in FY26 revenue.
• Capex is minimal: No significant capex is planned beyond maintenance and some debottlenecking, so the growth story is not capital-intensive from here.
• Vitafor-Vinpai cross-selling interest exists but is unquantified: Management noted very good interest in products from both acquisitions across its selling and distribution geographies, but offered no timeline or numbers.

Guidance & Commitments

Key Metrics